Kedokteran & Kesehatan editorial
Open AccessOA2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
In a randomized, double-blind trial, a single 25-mg dose of psilocybin significantly reduced depressive symptoms and functional disability compared to niacin placebo in adults with major depressive disorder, with effects sustained through 43 days.
C. Raison; G. Sanacora; J. Woolley; K. Heinzerling; B. Dunlop; Randall T. Brown; R. Kakar; M. Hassman; R. Trivedi; R. Robison; Natalie Gukasyan; Sandeep M. Nayak; Xiao-Jue Hu; Kelley C. O'Donnell; B. Kelmendi; Jordan Sloshower; Andrew D. Penn; Ellen R. Bradley; Daniel F. Kelly; T. Mletzko; Christopher R. Nicholas; P. Hutson; G. Tarpley; Malynn L. Utzinger; Kelsey Lenoch; K. Warchoล; Theraysa Gapasin; M. Davis; Courtney Nelson-Douthit; Steffanie H. Wilson; C. Brown; W. Linton; Stephen Ross; R. Griffithsยท Journal of the American Medical Association (JAMA)ยท 2023ยท DOI 10.1001/jama.2023.14530
The core problem
Major depressive disorder (MDD) is a prevalent and debilitating condition, and current treatments often require chronic administration and may have limited efficacy. Psilocybin, a serotonergic psychedelic, has shown promise in early studies as a potential rapid-acting antidepressant when combined with psychological support. This phase 2 trial aimed to evaluate the magnitude, timing, and durability of antidepressant effects and the safety of a single dose of psilocybin in patients with MDD. The study was conducted at 11 research sites in the US between December 2019 and June 2022, randomizing 104 adults with moderate-to-severe MDD to receive either psilocybin or a niacin placebo.
Innovation
This was a randomized, double-blind, placebo-controlled trial. Participants were adults aged 21 to 65 years with a DSM-5 diagnosis of MDD of at least 60 days' duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents were eligible after medication taper. They were randomized 1:1 to receive a single 25-mg dose of synthetic psilocybin or 100 mg of niacin (placebo) in identical capsules, administered with psychological support. The primary outcome was change in Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to day 43. Key secondary outcomes included change in MADRS score at day 8, change in Sheehan Disability Scale score at day 43, and sustained response and remission. Assessments occurred at baseline and at 2, 8, 15, 29, and 43 days post-dosing. Participants, site personnel, outcome assessors, and statisticians were blinded.
Introduction
Major depressive disorder (MDD) is a prevalent and debilitating condition, and current treatments often require chronic administration and may have limited efficacy. Psilocybin, a serotonergic psychedelic, has shown promise in early studies as a potential rapid-acting antidepressant when combined with psychological support. This phase 2 trial aimed to evaluate the magnitude, timing, and durability of antidepressant effects and the safety of a single dose of psilocybin in patients with MDD. The study was conducted at 11 research sites in the US between December 2019 and June 2022, randomizing 104 adults with moderate-to-severe MDD to receive either psilocybin or a niacin placebo.
Why it matters
The findings indicate that a single dose of psilocybin, administered with psychological support, produces a clinically significant and sustained reduction in depressive symptoms and functional disability in patients with MDD. The effect size is notable, with a mean difference of 12.3 points on the MADRS at day 43, exceeding the threshold for clinical significance. The rapid onset of effect (by day 8) and durability through 43 days suggest a potential paradigm shift in MDD treatment. The safety profile was acceptable, with no serious treatment-emergent AEs, though psilocybin was associated with more overall and severe AEs, which were likely transient and related to the acute psychedelic experience. Limitations include the lack of active placebo (niacin may produce physiological effects), the short follow-up period, and the exclusion of patients with severe suicidal ideation. These results add to the growing evidence that psilocybin may be a novel intervention for MDD, but further research is needed to confirm long-term efficacy and safety.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ